BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

Register
Register
Register

ProjectUpdated on 24 August 2026

针对癌症和感染的新型免疫治疗药物

Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited

China (Hong Kong)

About

Δ42PD-1是PD-1的一种亚型,具有独特的化学特性,不与癌细胞上通常与PD-1结合的PD-L1配体相互作用。通过特异性识别并结合 T 细胞表面的 Δ42PD1,精准阻断其与癌细胞表面 TLR4 的异常信号通路,直击耐药根源。有效抑制促瘤炎症因子(如 IL-6)的释放,逆转T 细胞耗竭状态,恢复其正常的肿瘤杀伤功能。从根源上解决传统 PD-1 疗法诱导的耐药问题,有望将免疫治疗有效人群从 20% 大幅提升,实现对耐药肿瘤的有效清除。

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Total Project Value

  • 25,000,001 to 50,000,000 USD

Investment Capital Required

  • 5,000,001 to 7,500,000 USD

Interested Format of Cooperation

  • Open for Negotiation

Preferred Financing Model

  • Equity

Type(s) of Last Financing Round of the project (if Applicable)

  • Equity (private)

Main Service(s) Required

  • Financial Services

Financial Services

  • Private Equity & Venture Capital

Similar opportunities